초록 ▼

A portable waste collection device comprises a first container and an adjacent second container. The first container has an interior volume adapted to receive and contain waste. The second container has an interior volume adapted to contain a flushing solution. The second container has a discharge p

A portable waste collection device comprises a first container and an adjacent second container. The first container has an interior volume adapted to receive and contain waste. The second container has an interior volume adapted to contain a flushing solution. The second container has a discharge port adapted to permit flushing solution contained in the second container to be discharged from the second container into the first container. The second container comprises a pump for pumping a desired amount of the flushing solution from the second container into the first container.

대표청구항 ▼

A portable waste collection device comprises a first container and an adjacent second container. The first container has an interior volume adapted to receive and contain waste. The second container has an interior volume adapted to contain a flushing solution. The second container has a discharge p

A portable waste collection device comprises a first container and an adjacent second container. The first container has an interior volume adapted to receive and contain waste. The second container has an interior volume adapted to contain a flushing solution. The second container has a discharge port adapted to permit flushing solution contained in the second container to be discharged from the second container into the first container. The second container comprises a pump for pumping a desired amount of the flushing solution from the second container into the first container. ck of immunological stimulation of the gastrointestinal tract comprising administering a therapeutically effective amount of a neuropeptide. Also described are methods for reducing the rate of infection of the respiratory tract by pathogenic microorganisms associated with a lack of enteral feeding or a lack of immunological stimulation of the gastrointestinal tract comprising administering a therapeutically effective amount of a neuropeptide. In addition, a method of reducing the atrophy or dysfunction of the GALT comprising administering a therapeutically effective amount of a neuropeptide is described. The specification further describes compositions for reducing or preventing the impairment of intestinal or respiratory tract mucosal immunity comprising a neuropeptide and a pharmaceutically acceptable carrier.